Filtered By:
Infectious Disease: Coronavirus
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 74541 results found since Jan 2013.
siRNA as a potential therapy for COVID-19
Curr Drug Deliv. 2021 Aug 5. doi: 10.2174/1567201818666210805145320. Online ahead of print.ABSTRACTSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) is a highly contagious virus causing COVID-19 disease that severely impacted the world health, education, and economy systems in 2020. The numbers of infection cases and reported deaths are still increasing with no specific treatment identified yet to halt this pandemic. Currently, several proposed treatments are under preclinical and clinical investigations now, alongside the race to vaccinate to as much individuals as possible. The genome of SARS-CoV2 share similar...
Source: Current Drug Delivery - August 6, 2021 Category: Drugs & Pharmacology Authors: Ahmad Aljaberi Eman M Migdadi Khalid M Abu Khadra Mahmoud Abu Samak Iman A Basheti Nizar Al-Zoubi Source Type: research
Next Phase of NIH Preprint Pilot Launching Soon
Last month, the National Library of Medicine (NLM)announced plans to extend its NIH Preprint Pilot in PubMed Central (PMC) and PubMed beyond COVID-19 to encompass all preprints reporting on NIH-funded research. The second phase of the pilot, launching later this month, will include preprints supported by an NIH award, contract, or intramural program and posted to aneligible preprint server on or after January 1, 2023.In preparation for the launch of this second phase, we have updated PMC and PubMed site features to help users of these databases incorporate the increased volume of preprints into their discovery workflows. S...
Source: PubMed Central News - January 10, 2023 Category: Databases & Libraries Source Type: news
Second Phase of the NIH Preprint Pilot Launched
Today, we are pleased to announce the launch of the second phase of the NIH Preprint Pilot with the addition of more than 700 new preprint records to PubMed Central (PMC) and PubMed. This second phase expands the scope of the Pilot to include preprints resulting from all NIH-funded research. Eligible preprints are those acknowledging direct support of an NIH award or authored by NIH staff and posted to bioRxiv, medRxiv, arXiv, or Research Square, on or after January 1, 2023. NLM will automatically include the full text of the preprint (as license terms allow) and associated citation information in PMC and PubMed, respectiv...
Source: PubMed Central News - January 30, 2023 Category: Databases & Libraries Source Type: news
Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2
Antiviral Res. 2023 Jul 19:105677. doi: 10.1016/j.antiviral.2023.105677. Online ahead of print.ABSTRACTSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a respiratory virus that causes COVID-19 disease, with an estimated global mortality of approximately 2%. While global response strategies, which are predominantly reliant on regular vaccinations, have shifted from zero COVID to living with COVID, there is a distinct lack of broad-spectrum direct acting antiviral therapies that maintain efficacy across evolving SARS-CoV-2 variants of concern. This is of most concern for immunocompromised and immunosuppressed ...
Source: Antiviral Research - July 21, 2023 Category: Virology Authors: Ellen Bowden-Reid Scott Ledger Yuan Zhang Francesca Di Giallonardo Anupriya Aggarwal Alberto Ospina Stella Anouschka Akerman Vanessa Milogiannakis Gregory Walker William Rawlinson Stuart Turville Anthony D Kelleher Chantelle Ahlenstiel Source Type: research
Combination siRNA therapy against feline coronavirus can delay the emergence of antiviral resistance in vitro
This study investigated the efficacy of combination siRNA therapy and its ability to delay or prevent viral escape. Virus serially passaged through cells treated with a single or dual siRNAs rapidly acquired resistance, with mutations identified in the siRNA target sites. Combination therapy with three siRNA prevented viral escape over the course of five passages. To identify more potent silencing molecules we also compared the efficacy, in terms of potency and duration of action, of canonical versus Dicer-substrate siRNAs for two previously identified effective viral motifs. Dicer-substrate siRNAs showed equivalent or bet...
Source: Veterinary Microbiology - December 31, 2014 Category: Veterinary Research Source Type: research
Public interest in musculoskeletal symptoms and disorders during the COVID-19 pandemic : Infodemiology study
CONCLUSION: Public interest focused on COVID-19 and sought online information for COVID-19 symptoms in the early pandemic. In the period July through October, there was an upward trend in musculoskeletal symptoms and some colloquial terms/well-known musculoskeletal conditions coupled with a downward trend in general musculoskeletal disorder terms and certain specific diagnoses. This information may help rheumatologists understand public interest in musculoskeletal symptoms and disorders and address the needs of patients to mitigate the negative impact of the pandemic on outcomes.PMID:33779835 | PMC:PMC8006118 | DOI:10.1007/s00393-021-00989-2
Source: Zeitschrift fur Rheumatologie - March 29, 2021 Category: Rheumatology Authors: Sinan Karde ş An ıl Erdem Hatice G ürdal Source Type: research
A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant
EMBO Mol Med. 2022 Feb 8:e15298. doi: 10.15252/emmm.202115298. Online ahead of print.ABSTRACTThe emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants has altered the trajectory of the COVID-19 pandemic and raised some uncertainty on long term efficiency of vaccine strategy. The development of new therapeutics against a wide range of SARS-CoV-2 variants is imperative. We here have designed an inhalable siRNA, C6G25S, which covers 99.8% of current SARS-CoV-2 variants and is capable of inhibiting dominant strains, including Alpha, Delta, Gamma and Epsilon, at picomolar ranges of IC50 in vitro. Mo...
Source: Molecular Medicine - February 9, 2022 Category: Molecular Biology Authors: Yi-Chung Chang Chi-Fan Yang Yi-Fen Chen Chia-Chun Yang Yuan-Lin Chou Hung-Wen Chou Tein-Yao Chang Tai-Ling Chao Shu-Chen Hsu Si-Man Ieong Ya-Min Tsai Ping-Cheng Liu Yuan-Fan Chin Jun-Tung Fang Han-Chieh Kao Hsuan-Ying Lu Jia-Yu Chang Ren-Shiuan Weng Qian- Source Type: research
